Kronos Bio, Inc. (KRON)

Market Cap	61.30M
Revenue (ttm)	6.29M
Net Income (ttm)	-112.67M
Shares Out	60.09M
EPS (ttm)	-1.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	299,638
Open	1.050
Previous Close	1.030
Day's Range	0.983 - 1.060
52-Week Range	0.731 - 2.290
Beta	1.83
Analysts	Strong Buy
Price Target	4.13 (+304.9%)
Earnings Date	May 17, 2024

About KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 62
• Stock Exchange: NASDAQ
• Ticker Symbol: KRON

Analyst Forecast

According to 2 analysts, the average rating for KRON stock is "Strong Buy." The 12-month stock price forecast is $4.13, which is an increase of 304.90% from the latest price.

Price Target

$4.13

(304.90% upside)

Analyst Consensus: Strong Buy